Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Cytokinetics Inc (CYTK) vs Toronto-Dominion Bank (TD) Price & Performance

Cytokinetics IncTrade
Toronto-Dominion BankTrade

Price performance (Past 24H)

Key statistics

Cytokinetics Inc vs Toronto-Dominion Bank — how do they compare? Cytokinetics Inc trades at $76.67 (market cap $10.78B), while Toronto-Dominion Bank trades at $121.35 (market cap $199.91B). The key difference: Toronto-Dominion Bank is far larger — about 18.5× Cytokinetics Inc's market cap, and Toronto-Dominion Bank pays a 2.64% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.

CYTKTD
Market Cap
$10.78B$199.91B
Sector
TechnologyFinancials
52-Week High
$87.26$124.80
52-Week Low
$34.31$72.85
Enterprise Value
$10.88B
Dividend Yield
2.64%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Cytokinetics Inc

Cytokinetics (CYTK) trades at $76.76, down 5.67% today, with a bearish technical signal and negative profitability metrics. Recent Q2 2026 earnings beat EPS estimates but missed on revenue, while the company's drug Myqorzo shows strong commercial uptake and regulatory approvals in the UK. Cash flow remains negative from operations, offset by financing activities.

The outlook is mixed: strong analyst buy ratings (97%) and a $111.14 price target suggest upside, but high cash burn, competitive pressures, and lack of profitability pose significant risks. Investment appeal hinges on successful drug commercialization and path to profitability.

Toronto-Dominion Bank

TD stock trades at $121.31, up 0.11% on the day, with a bullish technical signal from moving averages and recent earnings beats. The company reported Q1 2026 EPS of $1.74, exceeding the $1.63 estimate, and maintains a strong net income margin of 23.38%. Analyst consensus is positive with 9 buy ratings and no sell ratings among 17 analysts. Recent news highlights value comparisons with peers and dividend stability.

Outlook remains favorable due to consistent earnings performance and robust profitability, though risks include high debt levels and potential regulatory scrutiny. The stock's valuation at a P/E of 19.95 is reasonable relative to historical margins, supporting a cautious bullish view for long-term investors seeking dividend income and steady growth.

Returns comparison

Trailing returns across standard periods

About Cytokinetics Inc

Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.

Read more on CYTK

About Toronto-Dominion Bank

Toronto-Dominion is one of Canada's two largest banks and operates three business segments: Canadian retail banking, U.S. retail banking, and wholesale banking. The bank's U.S. operations span from Maine to Florida, with a strong presence in the Northeast. It also has a 13% ownership stake in Charles Schwab.

Read more on TD